Halozyme Therapeutics, Inc. (NASDAQ:HALO – Get Free Report) has been given a consensus rating of “Moderate Buy” by the nine ratings firms that are covering the company, MarketBeat Ratings reports. Two investment analysts have rated the stock with a hold recommendation and seven have given a buy recommendation to the company. The average 1 year price target among brokers that have updated their coverage on the stock in the last year is $59.44.
HALO has been the subject of a number of recent research reports. Morgan Stanley upped their target price on Halozyme Therapeutics from $59.00 to $64.00 and gave the company an “overweight” rating in a research note on Wednesday, August 7th. HC Wainwright reaffirmed a “buy” rating and set a $65.00 price objective on shares of Halozyme Therapeutics in a report on Thursday, August 8th. JPMorgan Chase & Co. lowered their target price on shares of Halozyme Therapeutics from $53.00 to $52.00 and set an “overweight” rating on the stock in a research note on Tuesday, August 6th. Wells Fargo & Company raised their price target on shares of Halozyme Therapeutics from $48.00 to $58.00 and gave the stock an “overweight” rating in a research note on Friday, June 7th. Finally, The Goldman Sachs Group lifted their price objective on Halozyme Therapeutics from $44.00 to $49.00 and gave the company a “neutral” rating in a report on Monday, July 22nd.
Insider Activity at Halozyme Therapeutics
Institutional Inflows and Outflows
Large investors have recently bought and sold shares of the company. TD Asset Management Inc raised its position in shares of Halozyme Therapeutics by 517.0% during the fourth quarter. TD Asset Management Inc now owns 1,983,916 shares of the biopharmaceutical company’s stock worth $73,326,000 after acquiring an additional 1,662,390 shares during the last quarter. Norges Bank bought a new stake in Halozyme Therapeutics during the 4th quarter worth about $44,935,000. Epoch Investment Partners Inc. lifted its position in Halozyme Therapeutics by 250.5% during the 4th quarter. Epoch Investment Partners Inc. now owns 1,163,033 shares of the biopharmaceutical company’s stock valued at $42,986,000 after purchasing an additional 831,199 shares during the period. Boston Partners boosted its stake in shares of Halozyme Therapeutics by 562.2% in the 4th quarter. Boston Partners now owns 552,392 shares of the biopharmaceutical company’s stock valued at $20,218,000 after purchasing an additional 468,977 shares during the last quarter. Finally, LSV Asset Management bought a new stake in shares of Halozyme Therapeutics during the fourth quarter worth approximately $17,090,000. Institutional investors and hedge funds own 97.79% of the company’s stock.
Halozyme Therapeutics Trading Down 0.9 %
Halozyme Therapeutics stock opened at $61.64 on Friday. Halozyme Therapeutics has a one year low of $32.83 and a one year high of $62.58. The company’s fifty day moving average price is $54.23 and its two-hundred day moving average price is $45.60. The company has a debt-to-equity ratio of 8.44, a current ratio of 6.64 and a quick ratio of 5.36. The company has a market capitalization of $7.85 billion, a price-to-earnings ratio of 25.47, a PEG ratio of 0.56 and a beta of 1.27.
Halozyme Therapeutics (NASDAQ:HALO – Get Free Report) last issued its quarterly earnings data on Tuesday, August 6th. The biopharmaceutical company reported $0.91 EPS for the quarter, beating analysts’ consensus estimates of $0.73 by $0.18. The business had revenue of $231.40 million for the quarter, compared to analyst estimates of $204.94 million. Halozyme Therapeutics had a return on equity of 225.71% and a net margin of 36.94%. The firm’s revenue for the quarter was up 4.7% on a year-over-year basis. During the same quarter in the prior year, the firm posted $0.68 EPS. On average, analysts forecast that Halozyme Therapeutics will post 3.66 earnings per share for the current fiscal year.
About Halozyme Therapeutics
Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.
Featured Articles
- Five stocks we like better than Halozyme Therapeutics
- How Can Investors Benefit From After-Hours Trading
- Advance Auto Parts Eyes Long-Term Growth Despite Q2 Hurdles
- Stock Sentiment Analysis: How it Works
- Toll Brothers Stock Up on Q3 Beat: Luxury Homes Drive Growth
- What is a Dividend Harvesting Strategy and How Can Investors Profit from it?
- 4 No-Brainer Stocks to Hold This Fall for Steady Gains
Receive News & Ratings for Halozyme Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Halozyme Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.